JP2008534017A5 - - Google Patents

Download PDF

Info

Publication number
JP2008534017A5
JP2008534017A5 JP2008504393A JP2008504393A JP2008534017A5 JP 2008534017 A5 JP2008534017 A5 JP 2008534017A5 JP 2008504393 A JP2008504393 A JP 2008504393A JP 2008504393 A JP2008504393 A JP 2008504393A JP 2008534017 A5 JP2008534017 A5 JP 2008534017A5
Authority
JP
Japan
Prior art keywords
dkkl
antibody
splice product
cancer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008504393A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008534017A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/011761 external-priority patent/WO2006105343A2/en
Publication of JP2008534017A publication Critical patent/JP2008534017A/ja
Publication of JP2008534017A5 publication Critical patent/JP2008534017A5/ja
Pending legal-status Critical Current

Links

JP2008504393A 2005-03-30 2006-03-30 癌の診断および治療のためのｄｋｋｌ−１のスプライス産物の調節因子 Pending JP2008534017A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66643105P 2005-03-30 2005-03-30
PCT/US2006/011761 WO2006105343A2 (en) 2005-03-30 2006-03-30 Dkkl-i splice product modulators for cancer diagnosis and therapy

Publications (2)

Publication Number Publication Date
JP2008534017A JP2008534017A (ja) 2008-08-28
JP2008534017A5 true JP2008534017A5 (enExample) 2009-03-19

Family

ID=36950360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008504393A Pending JP2008534017A (ja) 2005-03-30 2006-03-30 癌の診断および治療のためのｄｋｋｌ−１のスプライス産物の調節因子

Country Status (4)

Country Link
US (1) US8252267B2 (enExample)
EP (1) EP1896495A2 (enExample)
JP (1) JP2008534017A (enExample)
WO (1) WO2006105343A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
EP3488019B1 (en) 2016-07-21 2025-02-12 The General Hospital Corporation Extracellular mrna markers of muscular dystrophies in human urine
AU2018210316A1 (en) * 2017-01-17 2019-06-27 Illumina, Inc. Oncogenic splice variant determination

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736120A (en) * 1996-06-07 1998-04-07 Srinivasan; Ananthachari Method for preparing radiolabeled peptides
US7057017B2 (en) * 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
AU758004B2 (en) * 1997-12-17 2003-03-13 Genset S.A. Extended cDNAs for secreted proteins
CA2331154A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
CA2366062C (en) * 1999-03-05 2014-06-17 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
JP2006507793A (ja) 2001-12-05 2006-03-09 キュラジェン コーポレイション 治療ポリペプチド、それをコードする核酸、および使用方法
AU2003248933A1 (en) 2002-07-11 2004-02-02 Incyte Corporation Secreted proteins
JP2007508020A (ja) * 2003-09-30 2007-04-05 カイロン コーポレイション ヒトｄｋｋｌ１の新規スプライス改変体

Similar Documents

Publication Publication Date Title
Morrison et al. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer
Li et al. TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation
Gao et al. Prostate-specific membrane antigen (PSMA) promotes angiogenesis of glioblastoma through interacting with ITGB4 and regulating NF-κB signaling pathway
US12286484B2 (en) Targeting metastasis stem cells through a fatty acid receptor (CD36)
Shu et al. Exosomal circSPIRE1 mediates glycosylation of E-cadherin to suppress metastasis of renal cell carcinoma
Li et al. Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines
US7776541B2 (en) Psoriasin expression by breast epithelial cells
CN103328500B (zh) 用于癌症的诊断和治疗的方法和化合物
EP3436601B1 (en) Cytidine deaminase expression level in cancer as a new therapeutic target
Liu et al. LncRNA IL21-AS1 facilitates tumour progression by enhancing CD24-induced phagocytosis inhibition and tumorigenesis in ovarian cancer
Yawata et al. CD146 is highly expressed in glioma stem cells and acts as a cell cycle regulator
Zhao et al. Nerve growth factor signaling promotes nuclear translocation of TRAF4 to enhance tumor Stemness and metastatic dormancy via C‐Jun‐mediated IL‐8 autocrine
KR20180109811A (ko) 항암 치료 내성 판단 방법 및 상기 방법에 사용되는 조성물
JP2005520543A5 (enExample)
JP2015528694A (ja) 胃癌診断及び治療のためのａｄｃｙ３の用途
WO2022022541A1 (zh) Rbm10基因的用途
KR20220088910A (ko) 치료 및 진단 표적으로서의 hla-h, hla-j, hla-l, hla-v 및 hla-y
CN110541029B (zh) 乙醛脱氢酶18a1基因及其编码产物在mycn扩增神经母细胞瘤中的应用
KR101495275B1 (ko) 폐암 진단 및 치료를 위한 표적 단백질
WO2011129427A9 (ja) 癌の診断剤および治療剤
Liu et al. lncRNA WAC-AS1 promotes the progression of gastric cancer through miR-204-5p/HOXC8 axis
JP2008535854A5 (enExample)
KR20170052454A (ko) 소라페닙 민감성 예측용 바이오마커 조성물
CN111549130A (zh) LncRNA MAGI2-AS3在急性髓系白血病的产品中的用途及其检测试剂盒
US9075067B2 (en) Marker for the diagnosis of cancer